Emerging therapies for Clostridium difficile infections

Expert Opinion on Emerging Drugs

Volumn 16, Issue 3, 2011, Pages 425-439

  McFarland, Lynne V ^a  

^a Department of Health Services Research and Development ^*  (United States)

Author keywords

antibiotics; Clostridium difficile; diarrhea; epidemiology; gastrointestinal; immune globulin therapies; nosocomial; outbreaks; probiotics; therapies

Indexed keywords

ANTIBIOTIC AGENT; BOVINE IMMUNOGLOBULIN; FIDAXOMICIN; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; METRONIDAZOLE; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN;

ALGORITHM; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC ASPECT; HUMAN; INCIDENCE; REVIEW; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79958815731     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.571204     Document Type: Review

References (88)

1. McFarland LV, Beneda HW, Clarridge JE, Raugi GJ. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 2007;16:237-53
2. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009;15(13):1554-80
3. McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009;25:24-35
4. McFarland LV, Clarridge JE, Beneda HW, Raugi GR. Fluoroquinolone use and risk factors for Clostridium difficile disease within a Veterans Administration Health Care System. Clin Infect Dis 2007;45(9):1141-51 A case-control study of risk factors for CDI based at one Veterans Affairs hospital.
5. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004;171:466-72
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55
7. Zaiss NH, Witte W, Nubel U. Fluoroquinolone resistance and Clostridium difficile, Germany. Emerg Infect Dis 2010;16(4):675-7
8. Sundram F, Guyot A, Carboo I, et al. Clostridium difficile ribotypes 027 and 106: Clinical outcomes and risk factors. J Hosp Infect 2009;72(2):111-18
9. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28(11):1219-27
10. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008;70(4):298-304
11. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7
12. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7 A study comparing the efficacy of vancomycin and metronidazole for severe cases of CDI.
13. McDonald LC, Coignard B, Dubberke E, et al.; Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28(2):140-5
14. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:3-50
15. Noren T, Akerlund T, Back E, et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004;42(8):3635-43
16. Pelaez T, Cercenado E, Alcala L, et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 2008;46(9):3028-32
17. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-75
18. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16(18):2202-22 A comprehensive review of > 40 years of research on a probiotic, S. boulardii.
19. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009;9(4):237-44
20. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009;15(6):274-80
21. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14(6):929-31 Description of US rates of CDI from hospital discharge ICD9 codes from 2000 to 2005.
22. McFarland LV. Antibiotic-associated diarrhea: Epidemiology, trends and treatment. Future Microbiol 2008:3(5):563-578
23. Drudy D, Harnedy N, Fanning S, et al. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 2007;28(8):932-40
24. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium-difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9
25. Beaulieu M, Williamson D, Pichette G, Lachaine J. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007;28(11):1305-7
26. Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: New insights into structure and function. Glycobiology 2007;17(4):15R-22R
27. Citron DM, Tyrrell KL, Goldstein EJC. In vitro activity of CD-183,315 against 556 strains of C. difficile, 446 strains of intestinal anaerobes, and 56 facultative strains of Enterobacteriaceae. Presented at the 50th ICAAC Meeting; 12 - 15 September 2010; Boston MA
28. Mortin LI, Van Praagh ADG, Zhang S, et al. Potent efficacy of CB-183,315, a novel lipopeptide antibiotic, in a hamster model of C. difficile infection (CDI). Presented at the 50th ICAAC Meeting; 12 - 15 September 2010; Boston MA
29. Cubist. CB-183,315 human pharmacokinetics and exposure. Available from: Www.cubist.com/downloads/ CBST-Investor-Event2010-CDAD. pdf. [Accessed 28 February 2011]
30. Sullivan KM, Spooner LM. Fidaxomicin: A macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother 2010;44(2):352-9
31. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008;52(4):1391-5
32. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):223-8
33. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: A review. Expert Opin Investig Drugs 2008;17(4):547-53
34. Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31 A comprehensive review of the development of fidaxomicin.
35. Crook D, Miller M, Louie T, et al. Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in C. difficile infection (CDI) in 2 randomized controlled tirals (RCT) with 1105 patients. Presented at the 48th Annual Meeting of IDSA; 21 - 24 October 2010; Vancouver BC, Canada
36. Musher DM, Nuila F, Logan N. The long-term outcome of treatment of Clostridium difficile colitis. Clin Infect Dis 2007;45(4):523-4
37. Musher D, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-31 An excellent review of nitazoxanide and its development.
38. Bartoloni A, Colao MG, Orsi A, et al. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother 1990;26(5):627-33
39. Fulco P, Wenzel RP. Ramoplanin: A topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect 2006;4:939-45
40. Lagrotteria D, Holmes S, Smiega M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547-52
41. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8
42. Tannous G, Neff G, Kemmer N. Therapeutic success of rifaximin for Clostridium difficile infection refractory to metronidazole and vancomycin. Case Rep Gastroenterol 2010;4(3):404-9
43. Boero M, Berti E, Morgando A, Verme G. Terapia della colite da Clostridium difficile: Risultati di uno studio randomizzato aperto ribaximina vs. vancomicina. [Treatment for Clostridium difficile: Results of a randomized open study with rifaximine vs. vancomycin.]. Microbiologia Medica 1990;5:74-7
44. Citron DM, Merriam CV, Tyrrell KL, et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003;47:2334-8
45. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-18
46. SYNSORB Biotech, Inc. Announces Final Phase II Results for SYNSORB.2000. Available from: Http:// findarticles.com/p/articles/mi-m0EIN/ is-2000-July-6/ai-63163411. [Accessed 6 January 2011]
47. Weiss K. Toxin-binding treatment for Clostridium difficile: A review including reports of studies with tolevamer. Int J Antimicrob Agents 2009;33(1):4-7
48. Louie TJ, Peppe J, Watt CK, et al.; for the tolevamer study investigator group. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile associated diarrhea. Clin Infect Dis 2006;43:411-20
49. Louie TJ, Gerson M, Grimard D, et al. Results of a phase III study comparing tolevamer, vancomycin and metronidazole in CDAD [abstact K-4259]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17 - 20 September 2007; ASM Press, Chicago IL; Washington DC; 2007
50. Laffan AM, McKenzie R, Geenough WB, et al. Lactoferrin for the prevention of CDAD. Abstract presented at 2009 American Gastro Society Meeting; 20 - 25 October 2006; Las Vegas NV
51. Elmer GW, McFarland LV, McFarland M. The power of probiotics: Improving your health with beneficial microbes. Haworth Press, Binghamton, NY; 2007 A consumer guide for probiotics summarizing the field of probiotics and clinical findings.
52. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: Effects of probiotoic supplementation on the incidence of Clostridium difficile diarrhoea. Int Microbiol 2004;7:59-62
53. Rafiq R, Randey D, Osman SM, et al. Prevention of Clostridium difficile (C. difficile) diarrhea with probiotic in hospitalized patients treated with antibiotics. AGA Meeting; 2007. Gastroenterol 2007;132:A187 [S1167]
54. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998;36:171-4
55. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: A randomized, placebo-controlled trial. Mayo Clin Proc 2001;76:883-9
56. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: Randomized double blind placebo controlled trial. BMJ 2007;335(7610):80
57. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105(7):1636-41
58. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005;54(Pt 9):905-6
59. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000;95(S1):S11-13
60. Wullt M, Hagslatt MJ, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35:365-67
61. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-18
62. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-17
63. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009;15(6):285-9 An excellent review of > 100 cases treated with fecal biotherapy.
64. van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: Is donor faeces the solution? Euro Surveill 2009;14(34):16
65. Odenholt I, Walder M, Wullt M. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile. Chemotherapy 2007;53(4):267-74
66. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated dharrhoea. J Antimicrob Chemother 2004;54:211-16
67. Noren T, Wullt M, Akerlund T, et al. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 2006;50(9):3028-32
68. Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: An observational study and review of the literature. J Hosp Med 2010;5(1):e1-9 A review of 21 cases of CDI treated with IV IgG describing response rate, resolution times and survival.
69. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007;35:131-7
70. Kelly CP, Chetham S, Keates S, et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 1997;41:236-41
71. Warny M, Fatimi A, Bostwick EF, et al. Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999;44:212-17
72. Young KW, Munro IC, Taylor SL, et al. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol 2007;47:317-26
73. Van Dissel JT, De Groot N, Hensgens CM, et al. Bovine antibody-enriched whey to aid in the prevention of relapse of Clostridium difficile-associated diarrhoea: Preclinical and preliminary clinical data. J Med Microbiol 2005;54:197-205
74. Numan SC, Veldkamp P, Kuijper EJ, et al. Clostridium difficile-associated diarrhea: Bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007;56:888-9
75. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28(4):965-9
76. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362(3):197-205
77. Field D, Hill C, Cotter PD, Ross RP. The dawning of a 'golden era' in lantbiotic bioengineering. Microreview. Mol Microbiol 2010;78(5):1077-87 An insightful description of the developing world of lantibiotics.
78. Huscroft GS, Baines SD, Todhunter SL, et al. NVB302 demonstrates non-inferiority to vancomycin in treatment of C. difficile NAP1/027 infection in an in vitro human gut model. Presented at the 50th ICAAC Meeting; 12 - 15 September 2010; Boston MA
79. Mkrtchyan H, Gibbons S, Heidelberger S, et al. Purification, characterisation and identification of acidocin LCHV, an antimicrobial peptide produced by Lactobacillus acidophilus n.v. Er 317/402 strain Narine. Int J Antimicrob Agents 2010;35(3):255-60
80. Rea MC, Sit CS, Clayton E, et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci USA 2010;107(20):9352-7
81. Baines SD, O'Connor R, Saxton K, et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008;62(5):1078-85
82. Marquis M, Higgins ME, Mong SM, Lehoux D. Oritavancin pretreatment does not induce C. difficile infection in an experimental hamster model. Presented at the 50th ICAAC Meeting; 12 - 15 September 2010; Boston MA
83. Citron DM, Warren YA, Tyrrell KL, et al. Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrob Chemother 2009;63(5):972-6
84. Ochsner UA, Bell SJ, O'Leary AL, et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009;63(5):964-71
85. Nagy E, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 2010;42(1):33-8
86. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48(12):1732-5
87. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-95
88. Stiefel U, Nerandzic MM, Koski P, Donskey CJ. Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J Antimicrob Chemother 2008;62(5):1105-8